Annals of Oncology 14:1537-1542, 2003
© 2003 European Society for Medical Oncology
Original Paper |
Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial)
1 Department of Oncology, 3 Department of Surgery, 6 Department of Radiology and Department of Hepato-Gastroenterology, CHU Henri-Mondor, Assistance Publique-Hôpitaux de Paris, Créteil; 2 Department of Oncology and Department of Radiology, Centre Claudius Régaud, Toulouse; 4 Centre Jean Bernard, Le Mans; 5 Department of Surgery, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France; 7 International Drug Development Institute, Brussels, Belgium
Received 25 February 2003; revised 16 May 2003; accepted 4 June 2003
Background:
The purpose of this study was to evaluate the tolerance and efficacy of combining i.v. irinotecan, 5-fluorouracil (5-FU) and leucovorin (LV) with hepatic arterial infusion (HAI) of pirarubicin in non-resectable liver metastases from colorectal cancer.
Patients and methods:
Thirty-one patients were included in a phase II trial with i.v. irinotecan/5-FU/LV administered every 2 weeks, combined with HAI pirarubicin 60 mg/m2 on day 1 every 4 weeks. In most cases HAI was administered via a percutaneous catheter.
Results:
The main grade 3/4 toxicity was neutropenia, encountered in 78% of the patients. When all patients were considered in the analysis, tumour response rate was 15 out of 31 [48%; 95% confidence interval (CI) 32% to 65%]. Liver resection was made possible in 11 patients (35%; 95% CI 21% to 53%). There were no toxic death. Median overall survival was 20.5 months, and median progression-free survival was 9.1 months. In patients with completely resected metastases, median overall survival was not reached and median progression-free survival was 20.2 months.
Conclusion:
The multimodality approach used in the present study was well-tolerated and yielded dramatic responses. An aggressive approach combining i.v. and HAI chemotherapy deserves further investigation.
Key words: colorectal cancer, hepatic artery infusion, irinotecan, liver resection, pirarubicin
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Zhao, J. Zhu, X. Ji, J. Cai, F. Wan, Q. Li, B. Zhong, S. Tucker, and D. Wang A Phase II Study of Irinotecan and Capecitabine for Patients with Unresectable Liver-only Metastases from Colorectal Cancer Jpn. J. Clin. Oncol., January 1, 2010; 40(1): 10 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Poston, J. Figueras, F. Giuliante, G. Nuzzo, A. F. Sobrero, J.-F. Gigot, B. Nordlinger, R. Adam, T. Gruenberger, M. A. Choti, et al. Urgent Need for a New Staging System in Advanced Colorectal Cancer J. Clin. Oncol., October 10, 2008; 26(29): 4828 - 4833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Adam, T. Aloia, F. Levi, D. A. Wicherts, R. J. de Haas, B. Paule, M.-P. Bralet, M. Bouchahda, D. Machover, M. Ducreux, et al. Hepatic Resection After Rescue Cetuximab Treatment for Colorectal Liver Metastases Previously Refractory to Conventional Systemic Therapy J. Clin. Oncol., October 10, 2007; 25(29): 4593 - 4602. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Seki and M. Shiina Placement of a long tapered side-hole catheter in the hepatic artery: technical advantages, catheter stability, and arterial patency. Am. J. Roentgenol., November 1, 2006; 187(5): 1312 - 1320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Poston, R. Adam, and J.-N. Vauthey Downstaging or Downsizing: Time for a New Staging System in Advanced Colorectal Cancer? J. Clin. Oncol., June 20, 2006; 24(18): 2702 - 2706. [Full Text] [PDF]
|
|
|
|
|
|
M. Ducreux, M. Ychou, A. Laplanche, E. Gamelin, P. Lasser, F. Husseini, F. Quenet, F. Viret, J.-H. Jacob, V. Boige, et al. Hepatic Arterial Oxaliplatin Infusion Plus Intravenous Chemotherapy in Colorectal Cancer With Inoperable Hepatic Metastases: A Trial of the Gastrointestinal Group of the Federation Nationale des Centres de Lutte Contre le Cancer J. Clin. Oncol., August 1, 2005; 23(22): 4881 - 4887. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Folprecht, A. Grothey, S. Alberts, H.-R. Raab, and C.-H. Kohne Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates Ann. Onc., August 1, 2005; 16(8): 1311 - 1319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fakih First-line hepatic infusion of pirarubicin in patients with isolated liver metastases: is it really promising? Ann. Onc., February 1, 2004; 15(2): 359 - 359. [Full Text] [PDF]
|
|